Apixaban renal dosing

The total and renal elimination of apixaban were characterized in two IV studies including 50 healthy subjects administered a single IV dose of apixaban (0.5 5 mg) [23, 24]. In these studies, apixaban renal clearance was 27% of total clearance on average.

Anti-gout: colchicine (in patients with renal and/or hepatic impairment) Dosing recommendations for coadministration of apixaban with PAXLOVID depend on the

by J Fanikos 2024 Cited by 5123 Additionally, apixaban-dosing adjustments are based on serum creatinine however, apixaban exposure increased with increasing renal impairment. A

apixaban appears in the breast milk. Renal and hepatic dysfunction: Apixaban is not recommended in patients with CrCl 15 mL/min and those undergoing dialysis. Dosing recommendations by clinical indication for patients with less severe renal dysfunction are described above under Dosing. Apixaban should be used with caution

Dosing. Arzneimitteldosierung bei Niereninsuffizienz Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.

ELIQUIS (apixaban) DOSING SUMMARY. ▽ After 7 days, transition Renal impairment: Anti-FXa activity adjusted for exposure to apixaban was similar across.

Apixaban Renal Dose Adjustment. Most renal dosing recommendations are based on calculated CrCl using the Cockcroft-Gault formula, and limited drugs utilize eGFR for dosing. Interestingly, the apixaban renal dose adjustment recommendation is based on SCr, and is the only drug on the market with such dose adjustment criteria.

Renal impairment. Dose adjustment may be required (see 2.5 DOAC dosing). dosing of apixaban. Refer to the University of Liverpool COVID

The results suggest that dose adjustment of apixaban is not required on the basis of renal function alone and that the drug was well tolerated in this study